Sunstone LSV Fund II portfolio company Orphazyme ApS today announced the successful completion of a EUR 14 million financing round. Two new investors, LSP and the ALS Investment Fund joins the investor syndicate comprising Sunstone Capital, Kurma Partners, Idinvest Partners, Novo A/S and Aescap Venture.
Sunstone LSV Fund II portfolio company Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today that it has completed patient recruitment in the ATIBAR trial, a Phase IIb field-based clinical trial with Anergis’ lead compound AllerT for patients with birch pollen allergy.
Senior Pharma and Biotech Executive joins Anergis´ Board of Directors as New Chairman
Sunstone LSV Fund II portfolio company Anergis SA, a Swiss clinical-stage biopharmaceutical company developing proprietary products for ultra-fast allergy immunotherapy, today announced the appointment of Dr. Klaus Schollmeier as Chairman of its Board of Directors.
Mr. Schollmeier has been a senior executive and advisor to the pharmaceutical and biotech industries for more than 30 years and has senior leadership experience in R&D, Marketing as well as General Management.
F2G Ltd, a UK Biotech developing novel therapies for life threatening fungal infections, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted orphan drug status to its lead clinical candidate, F901318, for the treatment of invasive Aspergillosis and rare mould infections caused by Scedosporium species. Orphan drug designation will allow F901318 up to ten years market exclusivity following market authorisation in the EU.
MinervaX announces positive results from Phase I trial in 240 healthy adult women with its innovative Group B Streptococcal (GBS) vaccine to prevent life-threatening infections in newborns.